Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Novartis Pharma Services AG
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Efficacy and safety of QGE031 versus placebo and Omalizumab in patients aged 18-75 years with asthma
Responder rate compared to placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Safety and efficacy of BEZ235 in patients with pancreatic neuroendocrine tumors (pNET)
To estimate the efficacy of BEZ235 in adult patients with advanced (unresectable or metastatic) pNET (PFS)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A randomized, double-blind, parallel-group, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the renoprotective effect of renin inhibition with Aliskiren as an alternative to irbesartan in Type 2 patients with incipient/overt diabetic nephropathy
• To investigate whether renin-inhibition using Aliskiren 300 mg daily could be a treatment alternative to the angiotensin II receptor antagonist Irbesartan 300 mg with an equivalent potential for re...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
The study is to gather evidence of LFG316 efficacy in treatment of transplant associated microangiopathy (TAM) after hematopoetic precursor cell transplantation
To assess the hematological response rate in patients with TAM receiving LFG316 compared to standard of care (SoC)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Study to allow access to imatinib for patients who are on imatinib treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator
To evaluate long term safety data (SAEs and AEs).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A 3 year study to determine if optical coherence tomography can be used to measure disease progression in patients with multiple sclerosis
To evaluate change in RNFL thickness in RRMS patients followed for up to 36 months compared to a group of reference subjects (without neurologic or ophthalmic disease) to determine whether the optical...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler® (500/400μg) and mometasone furoate Twisthaler® (400μg) in adolescent and adult patients with persistent asthma
• To compare the rate of serious asthma exacerbations resulting in hospitalization, intubation or death in patients treated with QMF 500/400 μg or MF 400 μg.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Comparison of two ways of LCZ696 titration in heart failure patients
To assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction using conservative (reaching target dose over 6 weeks) and condensed (reaching targe...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A randomized, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability of 14-days treatment with an inhaled dose of QMF149 (500/800) in mild to moderate asthmatic patients
To assess the safety and tolerability of 14 days of once a day, evening treatment with QMF149 (500/800 using the Twisthaler®) in patients with mild to moderate asthma, with the aim of identifying unex...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myeloma
- To assess best overall response rate (ORR) up to 8 cycles
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
5
6
7
8
9
10
11
12
13
14
Suivant